DCM
RCKT icon

DAFNA Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

DAFNA Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-59,284
Closed -$451K – 78
2017
Q2 		$451K Hold
59,284
– – 0.32% 54
2017
Q1 		$474K Hold
59,284
– – 0.4% 55
2016
Q4 		$1.45M Sell
59,284
-25
-0% -$713 1.27% 32
2016
Q3 		$2.25M Buy
+59,309
New +$1.87M 1.57% 21

Other funds holding RCKT

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DAFNA Capital Management's RCKT Position: Q3 2017 in Review

DAFNA Capital Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2017, closing a stake of 59,284 shares — an estimated $451K sold.

DAFNA Capital Management first reported a position in RCKT in Q3 2016 and held it in 4 quarters. The position peaked at $2.25M in Q3 2016. 35 funds tracked by Wall St. Rank hold RCKT as of Q3 2017.

  • DAFNA Capital Management reported no remaining Rocket Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 59,284 Rocket Pharmaceuticals shares in Q3 2017, an estimated $451K.
  • DAFNA Capital Management first reported a position in Rocket Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • DAFNA Capital Management's Rocket Pharmaceuticals position peaked at $2.25M in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2017.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.